Psilocybin and music

Psilocybin and music refers to the relationship between psilocybin — the principal psychoactive compound in psilocybin mushrooms — and the experience, function, and use of music. Unlike substances woven into the production of popular music genres, psilocybin's most thoroughly documented relationship with music is as a structuring and guiding element within ritual and therapeutic settings. Music is played during almost all psychedelic-assisted therapy sessions, and sung chant has accompanied indigenous mushroom ceremonies for centuries.^{[1] [2]}

Within contemporary clinical research, music has been described as a "hidden therapist." A study of patients receiving psilocybin for treatment-resistant depression found that how patients experienced the music predicted their improvement, whereas the intensity of the drug effect alone did not.^[2:1] Yet the field rests on a striking gap: despite music's near-universal use, almost no controlled trial has tested whether music actually improves outcomes compared with silence, and at least one researcher has argued that music may interfere with therapy rather than support it.^[3:1] This tension — between a confident clinical convention and a thin experimental base — runs through the literature.

The evidence is also unevenly distributed across drugs. Much of the mechanistic neuroscience on how psychedelics alter music perception comes from studies of LSD rather than psilocybin, and findings are often extrapolated between the two even though their pharmacology differs.^{[1] [4]}

Evidence on whether psilocybin aids the making of music is sparser still. Controlled studies of creativity in general find that psilocybin does not reliably enhance creative output, and no controlled study has examined musical composition or performance.^[5]

Music in psychedelic therapy

The treatment model

Music listening has been a consistent feature of psychedelic therapy since the 1950s and 1960s, introduced as a way to support patients non-verbally during the acute drug effects.^{[2] [1]} In a typical session the patient lies down, wears eyeshades to encourage an inward focus, and listens to a curated playlist for the duration of the experience, while one or two therapists remain present and check in periodically.^[2] A survey of experienced guides found that music was present in all or nearly all high-dose sessions, and for most of each session's duration.^[4]

Playlists are commonly organized around the phases of a session — onset, build-up, peak, and return — with calmer music early and more emotionally evocative music reserved for the peak. This phase-based structure originated with Helen Bonny and Walter Pahnke in the early 1970s and was elaborated by later therapists such as William Richards at Johns Hopkins University.^{[2] [4]}

The "hidden therapist" study

The most influential study of music in psilocybin therapy is the interview-based analysis by Kaelen and colleagues (2018). Using interpretative phenomenological analysis of interviews with 19 patients treated for treatment-resistant depression, the researchers identified both "welcome" and "unwelcome" influences of the music. Welcome influences, described by 18 of 19 patients (95%), included intensified emotion and mental imagery, a sense of guidance, calm, and safety; unwelcome influences, described by 10 of 19, included unpleasant emotion and imagery, a sense of being misguided when the music felt dissonant with the patient's state, and resistance.^[2]

Three rated dimensions of the music experience — liking, resonance (the music feeling harmonious with the patient's emotional state), and openness (acceptance of the music-evoked experience) — each significantly predicted reductions in depression one week later (r = 0.57 to 0.60), whereas self-rated drug intensity showed essentially no relationship (r = 0.004).^[2:1] The authors concluded that music plays a central, mediating therapeutic role. The result is correlational, drawn from a small, open-label sample, and cannot by itself establish that music causes the benefit.^[2]

Intensified emotion and imagery

The most consistently reported effect of psilocybin on music is an intensification of emotion and of music-evoked mental imagery.^[2] Patients described the music as carrying them like a vehicle to different psychological places, and as evoking vivid imagery tied to the character of a piece; one patient said that under psilocybin she had "no choice but to go with the music."^[2] A rapid review (O'Callaghan et al. 2020) similarly found that participants experienced music as transportive and synesthetic, able both to ground them and to carry them forward, and that openness to the music and the use of participant-centered music were associated with better immediate and longer-term outcomes.^[6]

These phenomenological findings echo brain-imaging work conducted mainly with LSD rather than psilocybin, which reported that the drug enhanced the emotional response to music, increased music-evoked imagery through changes in parahippocampal connectivity, and heightened the perceived personal meaning of music.^[1] Because the two drugs differ pharmacologically, the degree to which these mechanisms transfer to psilocybin remains an inference rather than an established finding.^{[4] [1]}

Which music, and why

Features of "peak" music

Barrett et al. (2017) surveyed 10 highly experienced psilocybin guides and analyzed their recommended pieces using both expert music-theory ratings and computational audio analysis. Peak-period music was characterized by regular, predictable, formulaic phrase structure and orchestration, a feeling of continuous forward motion that slowly builds, and lower perceptual "brightness" than the music used in the lead-up to the peak.^[4:1] Recommended peak pieces often used homogeneous instrumentation in which individual instruments were hard to identify, along with drones, non-Western instruments, and wordless or unintelligible vocals — qualities the authors suggested suit an experience of dissolved selfhood. The pre-peak recommendations, by contrast, showed little consistency, suggesting either that no single optimum exists or that it has not yet been identified.^[4]

Standardization versus personalization

There is no agreed standard for selecting session music, and practice varies between research groups and therapists.^[4] Some trials use a fixed playlist to control music as a variable: the Imperial College depression study, for example, deliberately replaced familiar and Christian-themed classical works with predominantly ambient, neo-classical, and traditional or ethnic music, intending to reduce prior associations and religious connotations within a secular framework.^[2] O'Callaghan and colleagues argued that responses to music are partly idiosyncratic and that flexible, participant-centered protocols may be preferable to rigid playlists.^[6]

Does genre matter?

Psychedelic therapy has historically leaned on Western classical music. Strickland, Garcia-Romeu, and Johnson (2021) tested this assumption in a counterbalanced study of 10 participants undergoing psilocybin sessions for tobacco smoking cessation, comparing a Western classical playlist with an overtone-based playlist. Mystical-experience scores tended to be higher in the overtone-based sessions, 6 of 10 participants chose the overtone-based playlist for a third session, and biologically confirmed abstinence was slightly higher among those who chose it.^[7:1] With only 10 participants the finding is preliminary, and the authors called for systematic experimental study of session components.^[7]

Proposed mechanisms

Why music should matter so much under psilocybin is not settled. Review work offers several candidate explanations: that psychedelics amplify emotional and meaning responses to music while loosening the usual top-down regulation of those responses; that music supplies temporal structure and "guidance" to an otherwise formless experience; and that music may help facilitate the mystical experience that has itself been associated with therapeutic benefit.^{[1] [2]} Some authors connect these effects to the broader "entropic brain" account, in which psychedelics increase the variability of brain activity.^[4] These remain hypotheses; the precise mechanism by which music shapes the psilocybin experience has not been established.^[1]

The case against music

The assumption that music is beneficial has been directly challenged. In a 2025 opinion article, Samir Nader proposed "psychedelic minimalism": the view that music, as an emotionally potent external stimulus, may distort or displace the patient's own psychological material rather than support it, and that a silent, emotionally neutral setting might allow more authentic introspection.^[3:1] He drew on accounts from the "hidden therapist" study itself, including the patient who felt she had no choice but to follow the music, and on a case report of a participant who found the music overwhelming and preferred a music-free room.^{[3] [2]}

The unwelcome influences documented by Kaelen and colleagues lend some support to this concern: roughly half of the patients reported the music intensifying unwanted emotions, creating discomfort, or feeling misguiding when it clashed with their inner state.^[2] Nader also flagged a potential conflict of interest: the lead author of the work he criticized is the founder of a company that commercializes music for psychedelic therapy.^[3] The underlying methodological point is shared even by music's proponents — there are essentially no randomized comparisons of music versus silence — so the question of whether music helps, hinders, or merely accompanies remains open.^{[3] [1]}

Music creation and performance

Far less is known about whether psilocybin aids the making of music — composing, improvising, songwriting, or performing — than about how it shapes music listening. No controlled study has examined psilocybin's effects on musical performance, instrumental skill, or composition, and the available evidence comes almost entirely from general creativity research rather than from music-making itself.^[5]

Effects on creativity

The belief that psychedelics enhance creativity is long-standing but, until recently, rested mainly on anecdote.^[5] The first modern placebo-controlled test in the psilocybin literature, by Mason and colleagues (2021), found a more complicated picture. Under the acute drug effects, psilocybin decreased performance on tasks measuring convergent thinking (finding the single best solution) and reduced the fluency and originality of divergent thinking (generating many ideas), even as participants reported feeling more insightful and original; seven days later, the same participants generated more genuinely novel ideas than those given placebo.^[5:1] The authors concluded that psilocybin does not enhance creativity as such but shifts it in time, suppressing deliberate, goal-directed creative work during the acute state while possibly loosening idea generation in the days afterward.^[5]

The most robust pattern echoes a finding from research on cannabis and music: the drug reliably makes people feel more creative without making their output measurably more creative. In the Mason study the acute rise in subjective insightfulness coincided with an objective decline in task performance — a mismatch the authors noted recurs throughout the historical psychedelic-creativity literature.^[5] For a musician this would imply that ideas conceived as profound while acutely intoxicated may not hold up afterward, though the question has not been tested with musical material specifically.^[5]

Microdosing

Many creative professionals who use psilocybin do so by microdosing — taking repeated sub-perceptual doses — specifically in pursuit of enhanced creativity and focus. Placebo-controlled tests have not supported the practice. In a double-blind study of 34 people microdosing dried mushrooms, Cavanna and colleagues (2022) found no improvement in creativity or cognition, and the noticeable acute effects appeared mainly in participants who correctly guessed they had taken the active dose rather than placebo, leading the authors to attribute the reported benefits largely to expectation.^[8:1]

Performance and the evidence gap

Full doses are, in practice, incompatible with skilled performance: psilocybin acutely impairs executive function and associative learning and disorganizes ordinary cognition, and both the therapeutic and ceremonial models keep the participant largely still rather than playing an instrument.^{[5] [4]} Whether any part of music-making benefits from the drug — for instance, whether the post-acute window of looser idea generation aids composition — is unstudied, and the familiar cultural image of the psychedelic musician rests almost entirely on anecdote.^[5]

Ceremonial and cultural background

Long before clinical research, music — specifically sung and spoken chant rather than recorded music — was central to indigenous mushroom ceremonies in Mesoamerica. In the Mazatec velada of Oaxaca, Mexico, a healer (curandera) such as María Sabina would ingest Psilocybe mushrooms alongside participants and guide a night-long healing vigil through continuous chanting.^[9] Sabina's words, always sung or spoken, were recorded during a 1956 velada and released by Folkways Records in 1957 as one of the first documentary recordings of the practice.^{[10] [9]} The ethnomycologist R. Gordon Wasson's account of his participation, published the same year, introduced the ceremony to a wide Western audience and helped trigger the surge of outside interest in psilocybin.^[9]

In this tradition the chant is not an accompaniment to the experience but the medium of the healing itself: it names spirits, structures the vigil, and is understood as the means by which the curandera communicates with the sacred.^[9] The modern framing of curated playlists as "guiding" the therapeutic journey can be read as a secular echo of this older practice, in which sound carries and directs the participant.^{[1] [2]} Compared with cannabis, psilocybin has a comparatively thin association with the production of any popular music genre; its presence in 1960s psychedelic culture was shared with other psychedelics and is less specifically documented than its ceremonial and clinical roles.^[1]

Analysis

The psilocybin–music literature is unusual in combining a strong, near-universal clinical convention with a weak experimental foundation. Music is used in almost every psychedelic therapy session, is widely described as essential, and is correlated with better outcomes — yet, as both proponents and critics agree, no published randomized trial has compared psilocybin therapy with and without music.^{[3] [1]} The strongest single finding — that the music experience predicts antidepressant response while drug intensity does not — is correlational and based on 19 patients in an open-label study, and cannot by itself rule out that the music experience reflects a patient's general openness or therapeutic alliance rather than driving the benefit. The parallel question for music-making — whether psilocybin aids composition, improvisation, or performance — has scarcely been studied at all.^{[2] [5]}

Several specific questions remain genuinely unresolved. Whether any musical features are truly optimal, or whether the apparent regularities merely reflect shared training among a small group of therapists, is unsettled.^[4] Whether standardized or personalized, participant-chosen music produces better outcomes has not been determined.^[6] And the long-standing reliance on Western classical music appears to rest more on convention than evidence; the one small randomized comparison leaned, non-significantly, toward non-Western, overtone-based music.^[7:1] Adequately powered trials treating music as an experimental variable could settle these, but have largely not been run.^{[7] [3]}

From the standpoint of human agency, the framing of music as a "hidden therapist" deserves scrutiny: a stimulus that a participant feels they have no choice but to follow exerts real influence over a person in a highly suggestible state.^{[2] [3]} This raises questions of consent and control — whose aesthetic and cultural assumptions are embedded in a standardized playlist, and whether participants can meaningfully shape or decline it — that grow more pressing as psilocybin therapy moves toward wider approval and commercialization.^{[3] [6]} The ceremonial precedent offers a contrast: in the Mazatec velada the guiding sound was generated live by a healer responsive to the person before her, a relational model of musical guidance rather than a fixed recording.^[9]